Research progress on unfavourable treatment outcomes and risk factors of rifampicin-resistant tuberculosis patients

doi:10.19983/j.issn.2096-8493.2024111

Abstract

Abstract:

In recent years, the prevalence and transmission of drug-resistant tuberculosis has posed significant challenges to global tuberculosis control, particularly rifampicin-resistant tuberculosis. This form of the disease is characterized by long treatment duration, difficulty in management, high costs, and numerous adverse reactions, which often lead to unfavorable treatment outcomes such as treatment interruption, treatment failure, and loss to follow-up, severely affecting treatment outcomes and quality of life. The authors systematically present the occurrence of adverse treatment outcomes among patients with rifampicin-resistant tuberculosis patients both domestically and internationally, and discusses the factors that influence these unfavorable outcomes, thereby providing a reference for the development of preventive and therapeutic strategies aimed at improving the treatment effectiveness of rifampicin-resistant tuberculosis patients.

Key words: Tuberculosis, Rifampin, Multidrug-resistant, Treatment outcome, Risk factors,statistical

CLC Number:

R521

Sun Huijuan, Su Wei, Chen Wei. Research progress on unfavourable treatment outcomes and risk factors of rifampicin-resistant tuberculosis patients[J]. Journal of Tuberculosis and Lung Disease , 2024, 5(6): 573-582. doi: 10.19983/j.issn.2096-8493.2024111

Figures/Tables 2

References 99

[1]	Van Deun A, Decroo T, Piubello A, et al. Principles for constructing a tuberculosis treatment regimen:the role and definition of core and companion drugs. Int J Tuberc Lung Dis, 2018, 22(3): 239-245. doi:10.5588/ijtld.17.0660. pmid: 29471899
[2]	World Health Organization. WHO’s Global Tuberculosis Report 2020. Geneva: World Health Organization, 2020.
[3]	World Health Organization. WHO’s Global Tuberculosis Report 2016. Geneva: World Health Organization, 2016.
[4]	中国疾病预防控制中心结核病预防控制中心. 中国结核病防治工作技术指南. 北京: 人民卫生出版社, 2021.
[5]	World Health Organization. Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions. 17-19 November 2020. Geneva: World Health Organization, 2021.
[6]	郭翠菊, 杜先智. 耐多药结核病的治疗进展. 国际检验医学杂志, 2015(3): 375-377.
[7]	舒薇, 刘宇红. 世界卫生组织《2023年全球结核病报告》解读. 结核与肺部疾病杂志, 2024, 5(1): 15-19. doi:10.19983/j.issn.2096-8493.2024006.
[8]	于佳佳, 唐神结. 耐多药/利福平耐药结核病化学治疗年度进展2022. 中华结核和呼吸杂志, 2023, 46(1): 62-66. doi:10.3760/cma.j.cn112147-20221030-00853.
[9]	刘盛盛, 王莲芝, 唐神结. 耐多药和利福平耐药结核病化学治疗研究进展. 中华结核和呼吸杂志, 2020, 43(4): 371-375. doi:10.3760/cma.j.cn112147-20190830-00610.
[10]	王展, 王文瑾, 丁晓艳, 等. 利福平耐药结核病患者接触者预防性治疗研究进展. 中华流行病学杂志, 2023, 44(3): 470-476. doi:10.3760/cma.j.cn112338-20220729-00673.
[11]	李智炜, 赖铿, 李铁钢, 等. 2016—2020年广州市耐药结核病患者不良治疗结局状况及其影响因素分析. 中国防痨杂志, 2022, 44(6): 600-607. doi:10.19982/j.issn.1000-6621.20220020.
[12]	郭强, 李瑞萍, 马玉宝, 等. 2018—2020年甘肃省利福平敏感肺结核患者治疗不良结局的随机效应logistic模型分析. 结核与肺部疾病杂志, 2022, 3(6): 455-462. doi:10.19983/j.issn.2096-8493.20220111.
[13]	杨奎, 周丽平, 张玉, 等. 2015—2021年湖北省耐多药/利福平耐药结核病患者特征及治疗效果影响因素分析. 疾病监测, 2023, 38(5): 561-566. doi:10.3784/jbjc.202208120359.
[14]	Lecai J, Mijiti P, Chuangyue H, et al. Treatment outcomes of multidrug-resistant tuberculosis patients receiving ambulatory treatment in Shenzhen, China: a retrospective cohort study. Front Public Health, 2023, 11: 1134938. doi:10.3389/fpubh.2023.1134938.
[15]	Belachew T, Yaheya S, Tilahun N, et al. Multidrug-Resistant Tuberculosis Treatment Outcome and Associated Factors at the University of Gondar Comprehensive Specialized Hospital: A Ten-Year Retrospective Study. Infect Drug Resist, 2022, 15: 2891-2899. doi:10.2147/IDR.S365394. pmid: 35686191
[16]	Soeroto AY, Pratiwi C, Santoso P, et al. Factors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in West Java Indonesia: A retrospective cohort study. PLoS One, 2021, 16(2): e246284. doi:10.1371/journal.pone.0246284.
[17]	Indarti HT, Kristin E, Soedarsono S, et al. Treatment Outcomes of Multidrug-Resistant Tuberculosis Patients in East Java, Indonesia: A Retrospective Cohort Analysis. Int J Mycobacteriol, 2022, 11(3): 261-267. doi:10.4103/ijmy.ijmy_86_22. pmid: 36260444
[18]	Khachatryan L, Grigoryan R, Dadu A, et al. Factors associated with unfavourable treatment outcomes among people with rifampicin-resistant tuberculosis in Armenia, 2014—2017. Monaldi Arch Chest Dis, 2021, 91(1). doi:10.4081/monaldi.2021.1677.
[19]	Sharma N, Khanna A, Chandra S, et al. Trends & treatment outcomes of multidrug-resistant tuberculosis in Delhi, India (2009—2014): A retrospective record-based study. Indian J Med Res, 2020, 151(6): 598-603. doi:10.4103/ijmr.IJMR_1048_18.
[20]	Tobon A, Rueda J, Caceres DH, et al. Adverse treatment outcomes in multidrug resistant tuberculosis go beyond the microbe-drug interaction: Results of a multiple correspondence analysis. Biomedica, 2020, 40(4): 616-625. doi:10.7705/biomedica.5072. pmid: 33275341
[21]	Matambo R, Takarinda KC, Thekkur P, et al. Treatment outcomes of multi drug resistant and rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015. PLoS One, 2020, 15(4): e230848. doi:10.1371/journal.pone.0230848.
[22]	Ahmad N, Ahuja SD, Akkerman OW, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, 2018, 392(10150): 821-834. doi:10.1016/S0140-6736(18)31644-1. pmid: 30215381
[23]	Chanda E. The clinical profile and outcomes of drug resistant tuberculosis in Central Province of Zambia. BMC Infect Dis, 2024, 24(1): 364. doi:10.1186/s12879-024-09238-8. pmid: 38556907
[24]	Gopalaswamy R, Palani N, Viswanathan D, et al. Resistance Profiles to Second-Line Anti-Tuberculosis Drugs and Their Treatment Outcomes: A Three-Year Retrospective Analysis from South India. Medicina (Kaunas), 2023, 59(6):1005. doi:10.3390/medicina59061005.
[25]	Gualano G, Mencarini P, Musso M, et al. Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy. PLoS One, 2019, 14(2): e212948. doi:10.1371/journal.pone.0212948.
[26]	Makhmudova M, Maxsumova Z, Rajabzoda A, et al. Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan. Int J Tuberc Lung Dis, 2019, 23(3): 331-336. doi:10.5588/ijtld.18.0311. pmid: 30871664
[27]	Trebucq A, Schwoebel V, Kashongwe Z, et al. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries. Int J Tuberc Lung Dis, 2018, 22(1): 17-25. doi:10.5588/ijtld.17.0498. pmid: 29149917
[28]	Van LH, Phu PT, Vinh DN, et al. Risk factors for poor treatment outcomes of 2266 multidrug-resistant tuberculosis cases in Ho Chi Minh City: a retrospective study. BMC Infect Dis, 2020, 20(1):164. doi:10.1186/s12879-020-4887-1. pmid: 32087682
[29]	Kamara RF, Saunders MJ, Sahr F, et al. Social and health factors associated with adverse treatment outcomes among people with multidrug-resistant tuberculosis in Sierra Leone: a national, retrospective cohort study. Lancet Glob Health, 2022, 10(4): e543-e554. doi:10.1016/S2214-109X(22)00004-3. pmid: 35303463
[30]	Tola H, Holakouie-Naieni K, Mansournia MA, et al. National treatment outcome and predictors of death and treatment failure in multidrug-resistant tuberculosis in Ethiopia: a 10-year retrospective cohort study. BMJ Open, 2021, 11(8): e40862. doi:10.1136/bmjopen-2020-040862.
[31]	Leveri TH, Lekule I, Mollel E, et al. Predictors of Treatment Outcomes among Multidrug Resistant Tuberculosis Patients in Tanzania. Tuberc Res Treat, 2019, 2019: 3569018. doi:10.1155/2019/3569018.
[32]	Plesca V, Ciobanu A, Sereda Y, et al. Do catastrophic costs impact treatment outcomes in people with rifampicin-resistant tuberculosis in the Republic of Moldova? Monaldi Arch Chest Dis, 202, 91(1). doi:10.4081/monaldi.2021.1650.
[33]	Rafique S, Ahmad N, Khan S, et al. Frequency, management and impact of adverse events on treatment outcomes in patients with multidrug resistant tuberculosis in Balochistan, Pakistan. J Pharm Policy Pract, 2024, 17(1): 2332878. doi:10.1080/20523211.2024.2332878.
[34]	Kyrbashov B, Kulzhabaeva A, Kadyrov A, et al. Time to Treatment and Risk Factors for Unsuccessful Treatment Outcomes among People Who Started Second-Line Treatment for Rifampicin-Resistant or Multi-Drug-Resistant Tuberculosis in the Kyrgyz Republic, 2021. Trop Med Infect Dis, 2023, 8(8). doi:10.3390/tropicalmed8080407.
[35]	Choi H, Mok J, Kang YA, et al. Nationwide Treatment Outcomes of Patients With Multidrug/Rifampin-Resistant Tuberculosis in Korea, 2011—2017: A Retrospective Cohort Study (Korean TB-POST). J Korean Med Sci, 2023, 38(5): e33. doi:10.3346/jkms.2023.38.e33.
[36]	Fan L, Yang M, Han Y T, et al. Drug recommendation for optimization on treatment outcome for MDR/RR-TB based on a multi-center, large scale, retrospective cohort study in China. Expert Rev Anti Infect Ther, 2024, 22(5): 353-363. doi:10.1080/14787210.2024.2303032.
[37]	叶智腾, 任斐, 王华, 等. 复治耐多药/利福平耐药肺结核患者的治疗转归影响因素分析——全国多中心、回顾性队列研究. 中国防痨杂志, 2024, 46(7): 778-784. doi:10.19982/j.issn.1000-6621.20240088.
[38]	Ma JB, Zeng LC, Ren F, et al. Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi’an China, a Retrospective Cohort Study. Infect Drug Resist, 2022, 15: 4947-4957. doi:10.2147/IDR.S376177.
[39]	宁晨曦, 张诗琦, 吴哲渊, 等. 上海市耐多药肺结核患者治疗结局相关因素研究. 上海预防医学, 2023, 35(3): 219-223. doi:10.19428/j.cnki.sjpm.2023.22404.
[40]	于全骥, 陈诚, 宋红焕, 等. 2011—2020年江苏省利福平耐药肺结核患者转归情况及影响因素. 江苏预防医学, 2023, 34(3): 256-259. doi:10.13668/j.issn.1006-9070.2023.03.004.
[41]	包昌琳, 易恒仲, 唐益, 等. 耐多药肺结核患者化学治疗疗效及其影响因素分析. 中国防痨杂志, 2018, 40(5): 525-530. doi:10.3969/j.issn.1000-6621.2018.05.016.
[42]	李同心, 周刊, 李晓旭, 等. 重庆市初复治成人耐多药肺结核患者临床疗效与转归分析. 临床肺科杂志, 2022, 27(2): 237-241. doi:10.3969/j.issn.1009-6663.2022.02.016.
[43]	郭雪丽, 马晓雪, 陈慧娟, 等. 1446例耐多药肺结核患者特征及治疗情况分析. 现代预防医学, 2021, 48(15): 2835-2839.
[44]	殷美静, 宋立婷, 张艳, 等. 西安市96例耐多药肺结核治疗转归现况及其影响因素分析. 预防医学情报杂志, 2020, 36(10): 1285-1290.
[45]	林志浩, 丘小燕, 马晓慧, 等. 佛山市193例耐多药肺结核患者的治疗转归及影响因素分析. 实用预防医学, 2022, 29(11): 1290-1294.
[46]	周正华, 梁志勇, 邓小懂. 清远市耐多药肺结核患者治疗效果及其影响因素分析. 吉林医学, 2020, 41(3): 648-650. doi:10.3969/j.issn.1004-0412.2020.03.061.
[47]	邝浩斌, 谢育红, 冯治宇, 等. 2014—2019年广州市耐多药肺结核管理策略实施效果分析. 中国防痨杂志, 2021, 43(2): 113-118. doi:10.3969/j.issn.1000-6621.2021.02.003.
[48]	张哲. 227例耐多药肺结核治疗转归情况影响因素研究. 系统医学, 2018, 3(2): 58-59, 62. doi:10.19368/j.cnki.2096-1782.2018.02.058.
[49]	王艳敏. 85例耐多药肺结核治疗转归情况的影响因素分析. 中国医药指南, 2017, 15(25): 99-100. doi:10.15912/j.cnki.gocm.2017.25.081.
[50]	Drobniewski F, Eltringham I, Graham C, et al. A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK. Thorax, 2002, 57(9): 810-816. doi:10.1136/thorax.57.9.810. pmid: 12200527
[51]	罗且宁, 欧阳范献, 梁翠丹, 等. 耐多药肺结核疗效影响因素的meta分析. 海南医学院学报, 2023, 29(13): 1003-1010. doi:10.13210/j.cnki.jhmu.20230601.001.
[52]	马玲, 辜吉秀, 李晴, 等. 甘肃省初治肺结核患者耐药现状及耐多药影响因素分析. 中华流行病学杂志, 2022, 43(7): 1093-1098. doi:10.3760/cma.j.cn112338-20211117-00896.
[53]	Wrohan I, Nguyen TA, Nguyen VN, et al. Predictors of treatment outcomes among patients with multidrug-resistant tuberculosis in Vietnam: a retrospective cohort study. BMC Infect Dis, 2022, 22(1): 68. doi:10.1186/s12879-021-06992-x. pmid: 35057754
[54]	Xu C, Pang Y, Li R, et al. Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China. J Infect, 2018, 76(4): 348-353. doi:10.1016/j.jinf.2017.12.017. pmid: 29374587
[55]	Nair D, Velayutham B, Kannan T, et al. Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India. Public Health Action, 2017, 7(1): 32-38. doi:10.5588/pha.16.0055. pmid: 28775941
[56]	谢磊, 梁雅雪, 熊延军, 等. 耐多药肺结核患者3个月末痰菌阴转影响因素分析. 实用医学杂志, 2022, 38(6): 701-706. doi:10.3969/j.issn.1006-5725.2022.06.010.
[57]	Kurbatova EV, Cegielski JP, Lienhardt C, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med, 2015, 3(3): 201-209. doi:10.1016/S2213-2600(15)00036-3. pmid: 25726085
[58]	Javaid A, Ahmad N, Afridi AK, et al. Validity of Time to Sputum Culture Conversion to Predict Cure in Patients with Multidrug-Resistant Tuberculosis: A Retrospective Single-Center Study. Am J Trop Med Hyg, 2018, 98(6): 1629-1636. doi:10.4269/ajtmh.17-0936.
[59]	王茂军. 复治肺结核患者耐多药的风险因素分析. 临床肺科杂志, 2017, 22(12): 2243-2247. doi:10.3969/j.issn.1009-6663.2017.12.030.
[60]	Liu Q, Lu P, Martinez L, et al. Factors affecting time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis in China. BMC Infect Dis, 2018, 18(1): 114. doi:10.1186/s12879-018-3021-0. pmid: 29510666
[61]	Son E, Choi H, Mok J, et al. Timing and predictors of death during treatment in patients with multidrug/rifampin-resistant tuberculosis in South Korea. Korean J Intern Med, 2024, 39(4): 640-649. doi:10.3904/kjim.2024.029.
[62]	何昱颖, 胡屹, 陈玮, 等. 2014年至2018年贵州省利福平耐药结核病的危险因素及治疗转归分析. 中华传染病杂志, 2021, 39(5): 289-294. doi:10.3760/cma.j.cn311365-20200323-00377.
[63]	李秀杰. 172例耐多药结核病患者特征及治疗转归的影响因素分析. 中国现代医生, 2019, 57(7): 30-32.
[64]	苏伟, 李仁忠, 阮云洲, 等. 208例耐多药肺结核患者治疗转归及影响因素分析. 中国防痨杂志, 2018, 40(6): 593-598. doi:10.3969/j.issn.1000-6621.2018.06.009.
[65]	曹瑛, 马天丽, 李俊, 等. 2019年信阳市325例疑似耐药结核病患者的治疗转归分析. 江苏预防医学, 2021, 32(4): 445-447. doi:10.13668/j.issn.1006-9070.2021.04.020.
[66]	Tritar F, Ben SS, Ferchichi M, et al. Risk factors for treatment failure in multidrug resistant tuberculosis in Tunisia: An analytic study. Tunis Med, 2024, 102(1): 44-48. doi:10.62438/tunismed.v102i1.4521.
[67]	Ismail NA, Omar SV, Moultrie H, et al. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Lancet Infect Dis, 2022, 22(4): 496-506. doi:10.1016/S1473-3099(21)00470-9.
[68]	牛玉兰, 孔君, 黄艳, 等. 影响耐多药肺结核早期疗效危险因素分析. 新发传染病电子杂志, 2023, 8(5): 1-5. doi:10.1016/S1473-3099(21)00470-9.
[69]	Javaid A, Ullah I, Masud H, et al. Predictors of poor treatment outcomes in multidrug-resistant tuberculosis patients: a retrospective cohort study. Clin Microbiol Infect, 2018, 24(6): 612-617. doi:10.1016/j.cmi.2017.09.012.
[70]	Edessa D, Sisay M, Dessie Y. Unfavorable outcomes to second-line tuberculosis therapy among HIV-infected versus HIV-uninfected patients in sub-Saharan Africa: A systematic review and meta-analysis. PLoS One, 2020, 15(8): e237534. doi:10.1371/journal.pone.0237534.
[71]	Oliveira O, Gaio R, Villar M, et al. Predictors of treatment outcome in multidrug-resistant tuberculosis in Portugal. Eur Respir J, 2013, 42(6): 1747-1749. doi:10.1183/09031936.00197912. pmid: 23988773
[72]	Aibana O, Bachmaha M, Krasiuk V, et al. Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine. BMC Infect Dis, 2017, 17(1): 129. doi:10.1186/s12879-017-2230-2. pmid: 28173763
[73]	Xu G, Hu X, Lian Y, et al. Diabetes mellitus affects the treatment outcomes of drug-resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis, 2023, 23(1): 813. doi:10.1186/s12879-023-08765-0. pmid: 37986146
[74]	Huangfu P, Ugarte-Gil C, Golub J, et al. The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis. Int J Tuberc Lung Dis, 2019, 23(7): 783-796. doi:10.5588/ijtld.18.0433. pmid: 31439109
[75]	谢磊, 熊延军, 韩伊, 等. 178例耐多药肺结核患者治疗结局的影响因素分析. 保健医学研究与实践, 2023, 20(7): 44-48. doi:10.11986/j.issn.1673-873X.2023.07.010.
[76]	Hernandez GN, Seffah K, Zaman MA, et al. Unraveling the Secrets Behind the Multidrug-Resistant Tuberculosis Treatment Outcome in Chronic Renal Failure Patients Requiring Hemodialysis: A Systematic Review. Cureus, 2023, 15(3): e36833. doi:10.7759/cureus.36833.
[77]	Putra ON, Purnamasari T. Treatment Outcomes of Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: An Implication for Delamanid. Tuberc Respir Dis (Seoul), 2024, 87(2): 206-208. doi:10.4046/trd.2023.0188.
[78]	廖伟明, 付亮, 邓国防, 等. 含贝达喹啉方案治疗耐多药结核病的研究进展. 中国防痨杂志, 2021, 43(6): 619-624. doi:10.3969/j.issn.1000-6621.2021.06.017.
[79]	陈晴, 黄涛, 邹莉萍, 等. 耐多药/广泛耐药气管支气管结核的临床特征及接受含贝达喹啉方案治疗后影响早期疗效的危险因素. 中华肺部疾病杂志(电子版), 2022, 15(5): 643-648. doi:10.3877/cma.j.issn.1674-6902.2022.05.006.
[80]	万秋, 杨伏萍, 唐莉歆. 含氯法齐明的联合方案治疗耐多药肺结核的疗效及安全性分析. 中华肺部疾病杂志(电子版), 2023, 16(2): 275-277. doi:10.3877/cma.j.issn.1674-6902.2023.02.035.
[81]	Duan H, Chen X, Li Z, et al. Clofazimine improves clinical outcomes in multidrug-resistant tuberculosis: a randomized controlled trial. Clin Microbiol Infect, 2019, 25(2): 190-195. doi:10.1016/j.cmi.2018.07.012.
[82]	洪爱玲, 赵丰权, 蔡玉伟, 等. 含贝达喹啉氯法齐明方案治疗耐多药肺结核的临床疗效. 中国药物与临床, 2024, 24(1): 24-28. doi:10.11655/zgywylc2024.01.005.
[83]	邸宣, 董怡文, 王维娜, 等. 利奈唑胺治疗耐药肺结核的疗效和安全性的系统评价. 中国医院用药评价与分析, 2022, 22(11): 1375-1379. doi:10.14009/j.issn.1672-2124.2022.11.021.
[84]	杨少杰, 夏玉朝, 任鹏飞, 等. 153例利奈唑胺致耐药结核病患者神经系统不良反应分析. 中国药物警戒, 2022, 19(11): 1246-1249. doi:10.19803/j.1672-8629.20210283.
[85]	Munir MK, Saeed MS, Haider SZ, et al. Comparison of short term and long term multidrug resistant tuberculosis treatment outcomes in tertiary care settings. J King Saud University, 2024, 36(4): 103133. doi:10.1016/j.jksus.2024.103133.
[86]	周奉, 李同心, 杨松, 等. 结核病短程治疗方案的研究进展. 中国防痨杂志, 2023, 45(3): 311-317. doi:10.19982/j.issn.1000-6621.20220447.
[87]	李硕兰, 李明武, 李光妹, 等. 中国耐多药肺结核不良治疗转归影响因素的Meta分析. 中国防痨杂志, 2022, 44(12):1303-1313. doi:10.19982/j.issn.1000-6621.20220212.
[88]	Piparva KG, Jansari G, Singh AP. Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot. Perspect Clin Res, 2018, 9(4):165-169. doi:10.4103/picr.PICR_165_17. pmid: 30319946
[89]	潘辰慧, 张顺先, 张少言, 等. 耐多药肺结核治疗转归的影响因素分析. 解放军医学杂志, 2023, 48(9):1040-1047. doi:10.11855/j.issn.0577-7402.1102.2023.0120.
[90]	古力米娜·阿布力米提, 麦维兰江·阿不力米提, 地尔木拉提·吐逊, 等. 2021年喀什地区肺结核患者利福平耐药影响因素分析. 结核与肺部疾病杂志, 2022, 3(4):269-273. doi:10.19983/j.issn.2096-8493.20220094.
[91]	Zheng XB, Diwan VK, Zhao Q, et al. Treatment quality and outcome for multidrug-resistant tuberculosis patients in four regions of China: a cohort study. Infect Dis Poverty, 2020, 9(1):97. doi:10.1186/s40249-020-00719-x.
[92]	王春雷, 金韬, 赵鹏鹏, 等. 江苏省淮安市耐多药肺结核患者服药依从性及影响因素分析. 中国防痨杂志, 2022, 44(10): 1057-1062. doi:10.19982/j.issn.1000-6621.20220214.
[93]	杨天池, 陈琴, 陈同, 等. 宁波市利福平耐药肺结核患者家庭灾难性医疗支出及其影响因素分析. 中国防痨杂志, 2019, 41(11):1191-1196. doi:10.3969/j.issn.1000-6621.2019.11.009.
[94]	Wingfield T, Boccia D, Tovar M, et al. Defining catastrophic costs and comparing their importance for adverse tuberculosis outcome with multi-drug resistance: a prospective cohort study, Peru. PLoS Med, 2014, 11(7): e1001675. doi:10.1371/journal.pmed.1001675.
[95]	李志鹏, 盛宇超, 张杨, 等. 中国东部三市耐多药结核病患者经济负担研究. 复旦学报(医学版), 2021, 48(4):481-487. doi:10.3969/j.issn.1672-8467.2021.04.009.
[96]	胡逸欢, 陈勇, 吴哲渊, 等. 上海市耐多药肺结核患者治疗减免政策实施现况分析. 中国卫生资源, 2017, 20(5):422-425, 431. doi:10.13688/j.cnki.chr.2017.17429.
[97]	韦燕芳, 廖雅怡, 谭肖燕, 等. 耐多药肺结核患者服药依从性及其影响因素研究. 现代医院, 2022, 22(1): 152-154. doi:10.3969/j.issn.1671-332X.2022.01.044.
[98]	桂敏, 陈敬芳, 邓国防, 等. 耐多药结核病患者服药依从性现状及其影响因素分析. 中国现代医生, 2022, 60(3):103-107.
[99]	周倩茹, 王玲华. 耐多药结核病患者抑郁倾向相关因素研究进展. 中国防痨杂志, 2022, 44(2):197-202. doi:10.19982/j.issn.1000-6621.20210411.

发表年份	研究年份	作者	地区	样本量 (例)	不良治疗结局发生率(%)	治疗失败率(%)	病亡率 (%)	失访率 (%)	未评估率(%)
2021	2016—2016	Plesca等^[32]	摩尔多瓦共和国	287	21	5	8	8	-
2022	2011—2021	Belachew等^[15]	埃塞俄比亚	389	22.88	3.1	9.25	6.94	3.6
2019	2009—2014	Leveri等^[31]	坦桑尼亚	232	24.3	-	-	-	-
2021	2009—2019	Tola等^[30]	埃塞俄比亚	3395	24.3	1.7	12.8	9.7	-
2023	2021—2021	Kyrbashov等^[34]	吉尔吉斯斯坦	399	25.0	5.0	8.0	12.0	-
2022	2017—2021	Kamara等^[29]	塞拉利昂	365	26.0	-	-	-	-
2023	2011—2017	Choi等^[35]	韩国	7226	26.6	1.9	9.7	10.1	4.9
2020	2009—2019	Van等^[28]	越南	3395	26.7	-	-	-	-
2018	2013—2015	Trebucq等^[27]	西非和中非的9个国家	1006	27.6	5.9	7.8	4.8	-
2019	2012—2013	Makhmudova等^[26]	塔吉克斯坦	601	32	7	15	10	-
2024	2014—2019	Rafique等^[33]	巴基斯坦	275	32.4	-	19.6	12.7	-
2019	2013—2017	Gualano等^[25]	苏丹	156	36.5	-	14.1	-	-
2024	2017—2021	Chanda^[23]	赞比亚	183	37.2	-	21.3	6.0	9.8
2020	2010—2015	Matambo等^[21]	津巴布韦	473	39	1	26	8	3
2018	2009—2016	Ahmad等^[22]	25个国家	12030	39	8	14	-	-
2020	2010—2015	Tobon等^[20]	哥伦比亚	128	40	20.39	11.76	7.84	-
2020	2009—2014	Sharma等^[19]	印度	2958	46.72	-	-	-	-
2021	2014—2017	Khachatryan等^[18]	亚美尼亚	451	49.7	13.3	9.5	8	-
2021	2015—2017	Soeroto等^[16]	印度尼西亚	492	50%	-	-	-	-
2023	2018—2020	Gopalaswamy等^[24]	印度南部	217	52.0	3.2	13.8	14.3	20.7
2022	2016—2018	Indarti等^[17]	印度尼西亚	444	58.6	-	-	-	-

发表年份	研究年份	作者	范围	样本量	不良治疗结局发生率(%)	治疗失败率(%)	病亡率 (%)	失访率 (%)	未评估率(%)
2024	2018—2021	Fan等^[36]	全国6家结核病专科医院	3112	25.71	9.67	1.51	14.52	-
2024	2018—2020	叶智腾等^[37]	全国6家省级结核病专科医院	2291	27.28	11.39	1.44	14.45	-
2023	2010—2015	Lecai等^[14]	深圳市	261	28.9	11.5	0.4	8.0	8.8
2023	2011—2020	于全骥等^[40]	江苏省	2691	32.14	-	-	-	-
2022	2017—2019	Ma等^[38]	西安市	446	32.96	5.16	3.59	24.22	-
2023	2017—2018	宁晨曦等^[39]	上海市	182	34.6	7.7	4.9	8.2	13.7
2018	2014—2017	张哲^[48]	吉林省吉林市	227	34.81	22.90	0.44	-	-
2022	2008—2019	林志浩等^[45]	广东省佛山市	193	38.34	10.36	4.66	15.03	8.29
2023	2015—2021	杨奎等^[13]	湖北省	3799	38.70	2.68	7.96	18.20	9.86
2018	2014—2016	王艳敏^[49]	吉林省白山市	85	40	28.24	5.88	5.88	-
2022	2013—2016	李同心等^[42]	重庆市	548	41.24	31.20	3.28	6.75	-
2021	2014—2019	邝浩斌等^[47]	广州市	2417	43.18	-	-	-	-
2018	2012—2013	包昌琳等^[41]	湖南省	267	43.4	8.6	3.7	29.2	1.90
2020	2016—2017	殷美静等^[44]	西安市	96	45.82	14.58	6.25	25.00	-
2020	2016—2018	周正华等^[46]	广东省清远市	102	47.06	27.45	14.71	2.94	1.96
2021	2013—2020	郭雪丽等^[43]	贵州省	1446	63.87	-	3.38	16.08	-